Logo image of AJ91.DE

DOCCHECK AG (AJ91.DE) Stock Fundamental Analysis

FRA:AJ91 - Deutsche Boerse Ag - DE000A1A6WE6 - Common Stock - Currency: EUR

12.1  +0.1 (+0.83%)

Fundamental Rating

6

Overall AJ91 gets a fundamental rating of 6 out of 10. We evaluated AJ91 against 12 industry peers in the Health Care Technology industry. AJ91 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. AJ91 is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year AJ91 was profitable.
In the past year AJ91 had a positive cash flow from operations.
Each year in the past 5 years AJ91 has been profitable.
AJ91 had a positive operating cash flow in each of the past 5 years.
AJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFAJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M

1.2 Ratios

With a decent Return On Assets value of 4.38%, AJ91 is doing good in the industry, outperforming 66.67% of the companies in the same industry.
AJ91 has a better Return On Equity (6.65%) than 66.67% of its industry peers.
The Return On Invested Capital of AJ91 (5.26%) is better than 75.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AJ91 is above the industry average of 8.76%.
The last Return On Invested Capital (5.26%) for AJ91 is well below the 3 year average (13.43%), which needs to be investigated, but indicates that AJ91 had better years and this may not be a problem.
Industry RankSector Rank
ROA 4.38%
ROE 6.65%
ROIC 5.26%
ROA(3y)11.53%
ROA(5y)12.99%
ROE(3y)17.63%
ROE(5y)19.38%
ROIC(3y)13.43%
ROIC(5y)15.32%
AJ91.DE Yearly ROA, ROE, ROICAJ91.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30

1.3 Margins

AJ91 has a better Profit Margin (4.73%) than 66.67% of its industry peers.
AJ91's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 7.42%, AJ91 is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
AJ91's Operating Margin has declined in the last couple of years.
The Gross Margin of AJ91 (79.98%) is better than 66.67% of its industry peers.
AJ91's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.42%
PM (TTM) 4.73%
GM 79.98%
OM growth 3Y-31.98%
OM growth 5Y-12.53%
PM growth 3Y-33.68%
PM growth 5Y-11.9%
GM growth 3Y8.18%
GM growth 5Y0.31%
AJ91.DE Yearly Profit, Operating, Gross MarginsAJ91.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

AJ91 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, AJ91 has more shares outstanding
AJ91 has more shares outstanding than it did 5 years ago.
AJ91 has a worse debt/assets ratio than last year.
AJ91.DE Yearly Shares OutstandingAJ91.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
AJ91.DE Yearly Total Debt VS Total AssetsAJ91.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 4.32 indicates that AJ91 is not in any danger for bankruptcy at the moment.
AJ91's Altman-Z score of 4.32 is amongst the best of the industry. AJ91 outperforms 83.33% of its industry peers.
AJ91 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.32
ROIC/WACC0.76
WACC6.96%
AJ91.DE Yearly LT Debt VS Equity VS FCFAJ91.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M 30M

2.3 Liquidity

AJ91 has a Current Ratio of 2.57. This indicates that AJ91 is financially healthy and has no problem in meeting its short term obligations.
AJ91 has a better Current ratio (2.57) than 91.67% of its industry peers.
AJ91 has a Quick Ratio of 2.34. This indicates that AJ91 is financially healthy and has no problem in meeting its short term obligations.
AJ91 has a better Quick ratio (2.34) than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.34
AJ91.DE Yearly Current Assets VS Current LiabilitesAJ91.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AJ91 have decreased strongly by -58.59% in the last year.
The Earnings Per Share has been decreasing by -0.08% on average over the past years.
AJ91 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.26%.
AJ91 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.52% yearly.
EPS 1Y (TTM)-58.59%
EPS 3Y-37.32%
EPS 5Y-0.08%
EPS Q2Q%10.24%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y-5.4%
Revenue growth 5Y13.52%
Sales Q2Q%-6.79%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AJ91.DE Yearly Revenue VS EstimatesAJ91.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 25.21, the valuation of AJ91 can be described as expensive.
AJ91's Price/Earnings ratio is a bit cheaper when compared to the industry. AJ91 is cheaper than 75.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.82, AJ91 is valued at the same level.
Industry RankSector Rank
PE 25.21
Fwd PE N/A
AJ91.DE Price Earnings VS Forward Price EarningsAJ91.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AJ91 is valued cheaper than 91.67% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AJ91 is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.72
EV/EBITDA 4.16
AJ91.DE Per share dataAJ91.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The decent profitability rating of AJ91 may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

6

5. Dividend

5.1 Amount

AJ91 has a Yearly Dividend Yield of 6.36%, which is a nice return.
Compared to an average industry Dividend Yield of 3.76, AJ91 pays a better dividend. On top of this AJ91 pays more dividend than 91.67% of the companies listed in the same industry.
AJ91's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
Industry RankSector Rank
Dividend Yield 6.36%

5.2 History

The dividend of AJ91 is nicely growing with an annual growth rate of 13.35%!
Dividend Growth(5Y)13.35%
Div Incr Years0
Div Non Decr Years0
AJ91.DE Yearly Dividends per shareAJ91.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

103.98% of the earnings are spent on dividend by AJ91. This is not a sustainable payout ratio.
The Dividend Rate of AJ91 has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP103.98%
EPS Next 2YN/A
EPS Next 3YN/A
AJ91.DE Yearly Income VS Free CF VS DividendAJ91.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M 4M 6M 8M 10M
AJ91.DE Dividend Payout.AJ91.DE Dividend Payout, showing the Payout Ratio.AJ91.DE Dividend Payout.PayoutRetained Earnings

More info and screens

DOCCHECK AG

FRA:AJ91 (5/23/2025, 7:00:00 PM)

12.1

+0.1 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-20 2024-09-20
Earnings (Next)N/A N/A
Inst Owners8.86%
Inst Owner ChangeN/A
Ins Owners71.92%
Ins Owner ChangeN/A
Market Cap61.35M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.36%
Yearly Dividend0.75
Dividend Growth(5Y)13.35%
DP103.98%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 25.21
Fwd PE N/A
P/S 1.19
P/FCF 7.72
P/OCF 6.64
P/B 1.67
P/tB 1.68
EV/EBITDA 4.16
EPS(TTM)0.48
EY3.97%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.57
FCFY12.95%
OCF(TTM)1.82
OCFY15.06%
SpS10.18
BVpS7.23
TBVpS7.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.38%
ROE 6.65%
ROCE 9.09%
ROIC 5.26%
ROICexc 10.27%
ROICexgc 10.32%
OM 7.42%
PM (TTM) 4.73%
GM 79.98%
FCFM 15.38%
ROA(3y)11.53%
ROA(5y)12.99%
ROE(3y)17.63%
ROE(5y)19.38%
ROIC(3y)13.43%
ROIC(5y)15.32%
ROICexc(3y)24.61%
ROICexc(5y)32.31%
ROICexgc(3y)25.2%
ROICexgc(5y)34.1%
ROCE(3y)23.19%
ROCE(5y)26.45%
ROICexcg growth 3Y-50.74%
ROICexcg growth 5Y-17.09%
ROICexc growth 3Y-49.55%
ROICexc growth 5Y-16.39%
OM growth 3Y-31.98%
OM growth 5Y-12.53%
PM growth 3Y-33.68%
PM growth 5Y-11.9%
GM growth 3Y8.18%
GM growth 5Y0.31%
F-Score5
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 27.51%
Cap/Sales 2.51%
Interest Coverage 250
Cash Conversion 108.14%
Profit Quality 325.54%
Current Ratio 2.57
Quick Ratio 2.34
Altman-Z 4.32
F-Score5
WACC6.96%
ROIC/WACC0.76
Cap/Depr(3y)141.51%
Cap/Depr(5y)134.78%
Cap/Sales(3y)6.27%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.59%
EPS 3Y-37.32%
EPS 5Y-0.08%
EPS Q2Q%10.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y-5.4%
Revenue growth 5Y13.52%
Sales Q2Q%-6.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.95%
EBIT growth 3Y-35.65%
EBIT growth 5Y-0.7%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y359.94%
FCF growth 3Y-11.57%
FCF growth 5Y34.65%
OCF growth 1Y106.36%
OCF growth 3Y-13.35%
OCF growth 5Y12.23%